Lau DH - Search Results

1

Population-based maximum tolerated dose of irinotecan and carboplatin.

Wild CA, Wang SE, Gandara DR, Lara PN Jr, Meyers FJ, Tanaka M Jr, Houston J, Lauder J, Lau DH. Wild CA, et al. Among authors: lau dh. Oncology (Williston Park). 2003 Jul;17(7 Suppl 7):11-6. Oncology (Williston Park). 2003. PMID: 12886868 Clinical Trial.

2

Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.

Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara PN, Lau DH, Gandara DR. Davies AM, et al. Among authors: lau dh. J Thorac Oncol. 2007 Dec;2(12):1112-6. doi: 10.1097/JTO.0b013e31815ba7d0. J Thorac Oncol. 2007. PMID: 18090584 Free article. Clinical Trial.

3

The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.

Davies AM, Ruel C, Lara PN, Lau DH, Gumerlock PH, Bold R, Shibata S, Lenz HJ, Schenkein DP, Gandara DR. Davies AM, et al. Among authors: lau dh. J Thorac Oncol. 2008 Jan;3(1):68-74. doi: 10.1097/JTO.0b013e31815e8b88. J Thorac Oncol. 2008. PMID: 18166843 Free article. Clinical Trial.

4

Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer.

Davies A, Gandara DR, Lara P, Goldberg Z, Roberts P, Lau D. Davies A, et al. Semin Oncol. 2002 Jun;29(3 Suppl 12):10-6. doi: 10.1053/sonc.2002.34257. Semin Oncol. 2002. PMID: 12170446 Review.

5

A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer.

Wang H, Ryu J, Gandara D, Bold RJ, Urayama S, Tanaka M, Goldberg Z, Follette D, Narayan S, Lau D. Wang H, et al. J Thorac Oncol. 2007 Feb;2(2):153-7. doi: 10.1097/JTO.0b013e31802bff75. J Thorac Oncol. 2007. PMID: 17410032 Free article. Clinical Trial.

6

Population-based phase I trial of irinotecan and epirubicin.

Lau D, Johl J, Huynh M, Davies A, Tanaka M, Lara P, Gandara D. Lau D, et al. Am J Clin Oncol. 2008 Jun;31(3):226-30. doi: 10.1097/COC.0b013e3181605440. Am J Clin Oncol. 2008. PMID: 18525299 Clinical Trial.

7

Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.

Chen G, Huynh M, Fehrenbacher L, West H, Lara PN Jr, Yavorkovsky LL, Russin M, Goldstein D, Gandara D, Lau D. Chen G, et al. J Clin Oncol. 2009 Mar 20;27(9):1401-4. doi: 10.1200/JCO.2008.20.2127. Epub 2009 Feb 9. J Clin Oncol. 2009. PMID: 19204194 Free PMC article. Clinical Trial.

8

Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.

Lim N, Lara PN Jr, Lau DH, Edelman MJ, Tanaka M, al-Jazayrly G, Houston J, Lauder I, Gandara DR. Lim N, et al. Among authors: lau dh. Cancer Invest. 2003;21(1):7-13. doi: 10.1081/cnv-120016398. Cancer Invest. 2003. PMID: 12643004 Clinical Trial.

9

Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.

Lara PN Jr, Frankel P, Mack PC, Gumerlock PH, Galvin I, Martel CL, Longmate J, Doroshow JH, Lenz HJ, Lau DH, Gandara DR. Lara PN Jr, et al. Among authors: lau dh. Clin Cancer Res. 2003 Oct 1;9(12):4356-62. Clin Cancer Res. 2003. PMID: 14555506 Clinical Trial.

10

Treatment of extensive small cell lung cancer.

Davies AM, Lara PN, Lau DH, Gandara DR. Davies AM, et al. Among authors: lau dh. Hematol Oncol Clin North Am. 2004 Apr;18(2):373-85. doi: 10.1016/j.hoc.2003.12.012. Hematol Oncol Clin North Am. 2004. PMID: 15094177 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

399 results

Search Page

Filters